STOCK TITAN
  1. Home
  2. Sec-filings
  3. TLSI
  4. [8-K] TriSalus Life Sciences, Inc. Reports Material Event

TriSalus Life Sciences (NASDAQ: TLSI) outlines key leadership transitions

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. announced that Jodi Devlin has notified the company of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026. The company previously appointed Dr. Richard Marshall as Chief Medical Officer, effective June 29, 2026, helping support continuity in its clinical and medical leadership.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Retirement effective date October 1, 2026 Chief of Clinical Operations retirement
CMO appointment effective date June 29, 2026 Chief Medical Officer appointment
Warrant exercise price $11.50 per share TLSIW warrants for common stock
Emerging growth company regulatory
"Emerging growth company o o On April 24, 2026"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Nasdaq Global Market market
"TLSI | Nasdaq Global Market Warrants, each whole warrant"
The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.
Chief of Clinical Operations financial
"retire from her role as Chief of Clinical Operations, effective"
Chief Medical Officer financial
"appointed Dr. Richard Marshall to Chief Medical Officer of the Company"
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
warrants financial
"Warrants, each whole warrant exercisable for one share"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Understanding 8-K Material Events →
0001826667FALSE00018266672026-04-242026-04-240001826667us-gaap:CommonStockMember2026-04-242026-04-240001826667us-gaap:WarrantMember2026-04-242026-04-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 24, 2026
TRISALUS LIFE SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-39813
85-3009869
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
6272 W 91st Ave, Westminster, Colorado
80031
(Address of principal executive office)(Zip Code)
(888) 321-5212
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.0001 par value
TLSI
Nasdaq Global Market
Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share
TLSIW
Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 24, 2026, Jodi Devlin provided notice to TriSalus Life Sciences, Inc. (the “Company”) of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026. The Company is grateful for Ms. Devlin’s contributions.
As previously announced on April 7, 2026, the Company appointed Dr. Richard Marshall to Chief Medical Officer of the Company, effective June 29, 2026.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 29, 2026
TriSalus Life Sciences, Inc.
By:/s/ David Patience
Name:David Patience
Title:Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What leadership change did TriSalus Life Sciences (TLSI) disclose?

TriSalus Life Sciences disclosed that Jodi Devlin plans to retire as Chief of Clinical Operations. Her retirement is effective October 1, 2026, following a transition period. The company thanked her for her contributions in overseeing clinical operations.

When will Jodi Devlin retire from TriSalus Life Sciences (TLSI)?

Jodi Devlin intends to retire from her role as Chief of Clinical Operations effective October 1, 2026. She notified TriSalus Life Sciences of this decision on April 24, 2026, allowing the company several months for leadership transition planning.

Who is the new Chief Medical Officer at TriSalus Life Sciences (TLSI)?

TriSalus Life Sciences has appointed Dr. Richard Marshall as Chief Medical Officer. His appointment becomes effective June 29, 2026. This role focuses on the company’s medical strategy and clinical development as leadership transitions in clinical operations unfold.

What securities of TriSalus Life Sciences (TLSI) are listed on Nasdaq?

TriSalus Life Sciences lists its common stock and warrants on the Nasdaq Global Market. The common stock trades under the symbol TLSI, while warrants trade as TLSIW, each whole warrant exercisable for one share of common stock at $11.50 per share.

Does the TriSalus Life Sciences (TLSI) update involve any major transaction?

The disclosure focuses on leadership changes rather than financial transactions. It covers the planned retirement of the Chief of Clinical Operations and the effective date of a previously announced Chief Medical Officer appointment, without detailing acquisitions, financings, or earnings data.

Filing Exhibits & Attachments

4 documents

Other Documents